Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Radiation Oncology
•
Thoracic Malignancies
Would you offer adjuvant radiation therapy for a completely resected, node positive mucoepidermoid carcinoma of the lung?
Related Questions
how do you manage atypical adenomatous hyperplasia (AAH) at the margin for 2 sites of the same lobe, in a patient with multiple GGO's s/p wedge resection?
Do you still offer adjuvant chemotherapy and chemoradiation for NSCLC after neoadjuvant chemoimmunotherapy?
In patients with EGFR mutant L858R stage III NSCLC who are unresectable due to multistation N2 disease, would you consider upfront osimertinib over definitive intent CCRT?
What is your approach to radiographically suspicious lung nodules for which initial biopsy was negative for malignancy?
Do you use any drugs prophylactically to reduce the risk of radiation pneumonitis in lung SBRT?
Is there a role for radiation to the primary mediastinal disease in metastatic thymic neuroendocrine carcinoma with the primary as the only residual disease after systemic therapy?
How well does a negative non-contrast MRI of the brain exclude metastasis in a patient with squamous cell carcinoma of the lung?
How do you counsel patients with Stage IIIA EGFR+ lung cancer regarding treatment intent with concurrent chemoRT + consolidative systemic therapy?
What is the role of consolidative durvalumab and prophylactic cranial irradiation in patients with stage I small cell lung cancer?
Would you consider omission of PORT for node+ NSCLC with a positive margin in the setting of a high tumor PD-L1 score and plans for immunotherapy?
